A6Plasma IL-21 associates with HIV-1 Neutralising potency of polyclonal IgG in the peripheryOn-demand oral abstract sessionHumoral immunity (including broadly neutralizing antibodies)
D19Pivoting the use of e-Health & mHealth: assessing impact of peer via phone eservice delivery interventions on adherence, retention in care, viral load uptake and final infant outcomes during COVID-19E-posterUse of e-health/m-health
D34Piloting social contracting mechanisms for government procurement of HIV services in the EECA regionE-posterNational financing initiatives and country ownership
D22Piloting an integrated HIV/non-communicable disease (NCD) peer support programme in Cape TownE-posterIntegration of HIV services with non-communicable disease programmes
D4Pilot implementation of a screening and linkage intervention to increase PrEP uptake in primary careE-posterMethods to improve provider quality, supply and adaptation of services
B59Pharmacokinetics, safety and acceptability of a single dose of abacavir/lamivudine/lopinavir/ritonavir (4-in-1) fixed-dose granule formulation in neonates: PETITE studyE-posterPharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
B59Pharmacokinetics and safety of dispersible and immediate release FDC abacavir/dolutegravir/lamivudine in children with HIV weighing '¥14 kg: preliminary results from IMPAACT 2019E-posterPharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
C48Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in Durban, South Africa from 2016-2020E-posterAdherence to HIV prevention strategies
B37Persistence of drug-drug interaction problems with contemporary antiretroviral therapy. The case of ergotismE-posterDrug interactions
D83Periods of homelessness linked to higher VACS Index among people living with HIV who use unregulated drugsE-posterPeople who use drugs (including by injection)
271 - 280 of 870 items